Clinical and immunological relationship and the possibility of correction of violations of cytokine regulation and cognitive dysfunction in patients with atrial fibrillation


atrial fibrillation, cognitive disorder, rosuvastatin, atorvastatin, lipid spectrum, inflammation.

How to Cite

Stadnik, S. (2015). Clinical and immunological relationship and the possibility of correction of violations of cytokine regulation and cognitive dysfunction in patients with atrial fibrillation. The Journal of Neuroscience, 3(4), 5-12. Retrieved from


The aim of the study was to evaluate the effects of early statin therapy on the activity of mediators of inflammation, blood lipids and cognitive function in patients with persistent and paroxysmal forms of atrial fibrillation (AF). In the clinical study included 188 patients with a mean age of 56,8±6,2 years. All patients at the beginning of therapy performed neuropsychological testing to assess cognitive functions. Later patients along with standard therapy were prescribed rosuvastatin (n=60) or atorvastatin (n=56), it was determined the blood lipid spectrum and the level of inflammatory mediators (C-reactive protein, interleukin‑6, tumor necrosis factor-alpha). On the 14-th day of hospitalization and after 6 months all patients were re-investigation of the above parameters and the assessment of cognitive function. The clinical picture is equipped with light and moderate cognitive disorders. Patients of the main group on the background of statin treatment increased mental performance and attention, which manifested itself in reduction of average time of search of numbers when you run the sample Schulte. In the study of memory functions it was shown that prolonged statin therapy resulted in improvement in short-term and long-term memory. Statin therapy resulted in a significant decrease in the content of mediators of inflammation and blood lipids before the 14-th days of treatment
and after 6 months. The data obtained allow to recommend therapy with statins from the first day of hospital stage of treatment in all patients with cognitive dysfunction on the background of persistent and paroxysmal forms of AF, which reduces the number of complications and improves the prognosis of the disease.



1. Гуревич М.А. Практические аспекты этиологии, систематизации и лечения мерцательной аритмии / М.А. Гуревич // Кардиология. — 2001. — № 7. — С. 14-18.
2. Гусев Е.И. Ишемия головного мезга / Е.И. Гусев, В.И. Скворцова. — М.: Медицина, 2001. — 328 с.
3. Дамулин И.В. Легкие когнитивные нарушения / И.В. Дамулин // Consilium medicum. — 2004. — Т. 6, № 2. — С. 149-153.
4. Захаров В.В. Когнитивные расстройства в пожилом и старческом возрасте: Методическое пособие для врачей / В.В. Захаров, Н.Н. Яхно. — М., 2005. — 71 с.
5. Захаров В.В. Нарушения памяти / В.В. Захаров, Н.Н. Яхно. — М.: ГеотарМед, 2003. — 150 с.
6. Старчина Ю.А. Когнитивные функции и эмоциональное состояние больных, перенесших инсульт, на фоне антигипертензивной терапии / Ю.А. Старчина, В.А. Парфенов, И.Е. Чазова // Журн. неврол. и психиат. им. С.С. Корсакова. Инсульт. — 2005, вып. 15. — С. 39-44.
7. Alan S. Go. Prevalence of Diagnosed Atrial Fibrillation in Adults / S.G. Alan, M. Hylek Elaine, A. Kathleen // JAMA. — 2001. — Vol. 285, № 7. — P. 2370-2375.
8. Albert M.A. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin infl ammation/ CRP evaluation (PRINCE): a randomized trial and cohort study / M.A. Albert, E. Danielson, N. Rifai, P.M. Ridker // J. Am. Med. Assoc. — 2001. — Vol. 286, № 1. — P. 64-70.
9. Amarenco P. Statins for stroke prevention; disappointment and hope / P. Amarenco, A.M. Tonkin // Circulation. — 2004. — Vol. 109, № 23, Suppl. L. — P. 44-49.
10. Austin P.C. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada / P.C. Austin, M.M. Mamdani // Circulation. — 2005. — Vol. 112, № 9. — Р. 1296-1300.
11. Ballantyne С.М. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in highrisk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY II) / С.М. Ballantyne, М. Bertolami, Н.R. Hemandez Carcia // Am. Heart. J. — 2006. — Vol. 151. — P. 1-9.
12. Boss Ch.J. Is atrial fibrillation an inflammatory disorders? / Ch.J. Boss, R.А. Anderson, G.Y.H. Lip // Eur. Heart. J. — 2006. — Vol. 27. — Р. 136-149.
13. Brass L.M. National Lipid Association Statin Safety Task Force Neurology Expert Panel. An assessment of statin safety by neurologists / L.M. Brass, M.J. Alberts,
L. Sparks // Am. J. Cardiol. — 2006. — Vol. 97, № 8A. — Р. 86-88.
14. Cacciatore F. The role of blood pressure in cognitive impairment in an elderly population / F. Cacciatore, P. Abete, N. Ferrara // J. of Hypertension. — 2002. —
Vol. 15. — P. 0135-0142.
15. Collins R. Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high risk conditions / R. Collins, J. Armitage, S. Parish // Lancet. — 2004. — Vol. 363, № 9411. — P. 757-767.